Journal article

Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study

Quan Dong Nguyen, Syed Mahmood Shah, Jeffery S Heier, Diana V Do, Jennifer Lim, David Boyer, Prema Abraham, Peter A Campochiaro

OPHTHALMOLOGY | ELSEVIER SCIENCE INC | Published : 2009

Abstract

OBJECTIVES: To compare ranibizumab with focal/grid laser or a combination of both in diabetic macular edema (DME). DESIGN: Prospective, randomized, interventional, multicenter clinical trial. PARTICIPANTS: A total of 126 patients with DME. METHODS: Subjects were randomized 1:1:1 to receive 0.5 mg of ranibizumab at baseline and months 1, 3, and 5 (group 1, 42 patients), focal/grid laser photocoagulation at baseline and month 3 if needed (group 2, 42 patients), or a combination of 0.5 mg of ranibizumab and focal/grid laser at baseline and month 3 (group 3, 42 patients). MAIN OUTCOME MEASURES: The primary end point was the change from baseline in best-corrected visual acuity (BCVA) at month 6. ..

View full abstract

University of Melbourne Researchers